Troglitazone

NEW YORK, August 18 (Praxis Press). Troglitazone, a member of a new class of antidiabetic drugs, increases insulin sensitivity and promotes adipocyte differentiation. This drug may therefore be therapeutic in patients with lipoatrophic and lipodystrophic disorders. Arioglu and colleagues studied the effects of open-label troglitazone treatment in 20 patients with lipoatrophy and insulin resistance. After 6 months of treatment, fasting triglyceride levels decreased by 2.6 mmol/L (p = 0.019); free

August 24, 2000

NEW YORK, August 18 (Praxis Press). Troglitazone, a member of a new class of antidiabetic drugs, increases insulin sensitivity and promotes adipocyte differentiation. This drug may therefore be therapeutic in patients with lipoatrophic and lipodystrophic disorders. Arioglu and colleagues studied the effects of open-label troglitazone treatment in 20 patients with lipoatrophy and insulin resistance. After 6 months of treatment, fasting triglyceride levels decreased by 2.6 mmol/L (p = 0.019); free fatty acid levels decreased by 325 mmol/L (p = 0.035); the respiratory quotient decreased by a mean of 0.12 (p < 0.001); and body fat increased by a mean 2.4 percentage points (p = 0.044) due to a selective increase in subcutaneous fat. In the patients with diabetes, hemoglobin A1c levels decreased by a mean of 2.8% (p < 0.001). One patient developed nonalcoholic steatohepatitis at six weeks; another patient continuing treatment after the study developed hepatic eosinophilic infiltration at 10 months. Troglitazone improves metabolic parameters and increases body fat in patients with various lipoatrophic syndromes; however, the risk of hepatotoxicity should be factored into any decision to use this drug.

Popular Now

  1. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  2. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  3. Opinion: On “The Impact Factor Fallacy”
  4. Unstructured Proteins Help Tardigrades Survive Desiccation
Business Birmingham